AstraZeneca PLC (AZNs)

BATS Europe
Currency in SEK
1,574.00
+50.50(+3.31%)
Closed
AZNs Scorecard
Full Analysis
Trading at a high earnings multiple
Fair Value
Day's Range
1,567.251,580.00
52 wk Range
1,266.251,795.75
Key Statistics
Edit
Bid/Ask
1,578.00 / 1,574.00
Prev. Close
1,523.5
Open
1,580
Day's Range
1,567.25-1,580
52 wk Range
1,266.25-1,795.75
Volume
458
Average Volume (3m)
411
1-Year Change
21.26%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AZNs Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth
Show more

AstraZeneca PLC Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Employees
89900
Market
Sweden

Compare AZNs to Peers and Sector

Metrics to compare
AZNs
Peers
Sector
Relationship
P/E Ratio
31.7x15.1x−0.6x
PEG Ratio
1.750.030.00
Price/Book
5.5x3.6x2.6x
Price / LTM Sales
4.1x2.4x3.1x
Upside (Analyst Target)
-40.7%52.1%
Fair Value Upside
Unlock31.5%8.2%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.54
Dividend Yield
1.95%
Industry Median 1.27%
Annualized payout
30.7359
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Feb 06, 2025
EPS / Forecast
2.09 / 2.13
Revenue / Forecast
14.89B / 14.15B
EPS Revisions
Last 90 days

People Also Watch

703.00
ASML
-1.72%
747.70
KLAC
-1.85%
628.9
NOVOb
-0.96%
1,443.00
GSK
-2.47%
854.00
HSBA
+0.71%

FAQ

What Is the AstraZeneca (AZNs) Stock Price Today?

The AstraZeneca stock price today is 1,574.00

What Stock Exchange Does AstraZeneca Trade On?

AstraZeneca is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for AstraZeneca?

The stock symbol for AstraZeneca is "AZNs."

Does AstraZeneca Pay Dividends? What’s The Current Dividend Yield?

The AstraZeneca PLC dividend yield is 2.12%.

What Is the AstraZeneca Market Cap?

As of today, AstraZeneca market cap is 2.44T.

What is AstraZeneca Earnings Per Share?

The AstraZeneca EPS is 4.54.

What Is the Next AstraZeneca Earnings Date?

AstraZeneca will release its next earnings report on Apr 28, 2025.

From a Technical Analysis Perspective, Is AZNs a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.